Vivo Bio Tech cash flow

Latest FY25
Cash from operations
₹11.8cr−25.3% on FY24
Capital spending
₹22.3cr+180.1% on FY24
Free cash flow
−₹10.4cr₹7.9 cr in FY24
Cash from financing
₹3.9cr−₹7.6 cr in FY24
₹ crore except per share
Tap a line for its trendFY25Mar 2025FY24Mar 2024
Adjustments to reconcile profit — non-cash items
9.09.3
7.57.8
Cash from operating activities
9.14.1
15.918.9
11.815.8
Cash from investing activities
22.38.0
−15.8−8.0
Cash from financing activities
6.91.3
3.9−7.6
−0.10.3
Reference items
20.821.1
44.6%47.0%
−10.47.9
−₹6.83₹5.15
1.56×6.28×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
₹ CroreMcap ₹21.4 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation9.39.0
+ Finance Costs7.87.5
Cash from Operating Activities
Profit Before Tax (per I/S)4.19.1
Cash from Operations (pre-tax)18.915.9
Cash from Operating Activities15.811.8
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)8.022.3
Cash from Investing Activities-8.0-15.8
Cash from Financing Activities
+ Proceeds from Borrowings1.36.9
Cash from Financing Activities-7.63.9
Net Changes in Cash0.3-0.1
Reference Items
EBITDA21.120.8
EBITDA Margin %46.9844.56
Free Cash Flow (CFO − Capex)7.9-10.4
Free Cash Flow per Basic Share5.15-6.83
Cash Flow to Net Income6.281.56
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.